Expert Insights: Managing Patients with PIK3CA Mutations

Video content above is prompted by the following:

• Dr. Conlin to Dr. O’Shaughnessy: For patients with PIK3CA mutations, how do you decide between alpelisib vs inavolisib vs capivasertib (André et al. NEJM 2019, Turner et al. NEJM 2024, Turner et al. NEJM 2023)?
  • What factors guide your decision making?
  • What is your impression of the incidence and need to manage hyperglycemia with these agents?
• Dr. O’Shaughnessy to Dr. Conlin: If a patient progresses on 1L CDK4/6 inhibitor plus fulvestrant, do you typically switch to a different CDK4/6 inhibitor or change the endocrine therapy partner or both in the 2L setting? ​